Ifoxetine

Not to be confused with Fluoxetine.

Ifoxetine

Clinical data
Routes of administration	Oral
ATC code	none
Legal status
Legal status	In general: uncontrolled
Identifiers
IUPAC name (3R,4S)-4-(2,3-dimethylphenoxy)piperidin-3-ol
CAS Number	66208-11-5
PubChem CID	71971
ChemSpider	64977
UNII	LHH887104B
ChEMBL	ChEMBL2218865
CompTox Dashboard (EPA)	DTXSID10216397
Chemical and physical data
Formula	C13H19NO2
Molar mass	221.300 g·mol^−1
3D model (JSmol)	Interactive image
SMILES O(c1cccc(c1C)C)[C@H]2CCNC[C@H]2O

Ifoxetine (CGP-15,210-G) is a selective serotonin reuptake inhibitor (SSRI) which was investigated as an antidepressant in the 1980s but was never marketed.[1][2][3] Ifoxetine selectively blocks the reuptake of serotonin in the brain supposedly without affecting it in the periphery.[3] Supporting this claim, ifoxetine was found to be efficacious in clinical trials and was very well tolerated, producing almost no physical side effects or other complaints of significant concern.[3]

References

1. Burrows GD, McIntyre IM, Judd FK, Norman TR (August 1988). "Clinical effects of serotonin reuptake inhibitors in the treatment of depressive illness". The Journal of Clinical Psychiatry. 49 Suppl: 18–22. PMID 3045107.
2. Waldmeier PC, Maître L, Baumann PA, et al. (October 1986). "Ifoxetine, a compound with atypical effects on serotonin uptake". European Journal of Pharmacology. 130 (1–2): 1–10. doi:10.1016/0014-2999(86)90177-9. PMID 2877890.
3. Delini-Stula A, Fischbach R, Gauthier JM, et al. (July 1987). "First clinical experience with ifoxetine, a new 5-HT reuptake blocker with particular emphasis on the side-effect profile of the 5-HT-uptake inhibiting drugs". International Clinical Psychopharmacology. 2 (3): 201–15. doi:10.1097/00004850-198707000-00003. PMID 3320185.